Japan Falls to Third-Largest Global Creditor as China Overtakes in 2025 
Sri Lanka Central Bank Surprises Markets With 100 Basis Point Rate Hike Amid Inflation and Currency Pressure 
Oil Prices Jump as U.S. Strikes in Iran Raise Fears Over Strait of Hormuz Supply Disruptions 
Toshifumi Suzuki, Founder of Seven-Eleven Japan, Dies at 93 
BOJ Signals Possible Rate Hike as Middle East Tensions Fuel Inflation Concerns 
SoftBank Shares Surge as OpenAI IPO Buzz and SB Energy Filing Boost AI Optimism 
Morgan Stanley Names Top AI Security and Data Center Stocks for 2026 
Australia Inflation Cools in April as Fuel Prices Ease, But Core CPI Remains Sticky 
Dollar Slips as Iran Peace Hopes Ease Rate Hike Fears 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
Goldman Sachs to Pay $500M in 1MDB Shareholder Fraud Settlement 
RBNZ Holds Interest Rates Steady but Signals More Hikes Ahead in 2026 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
SpaceX Starship V3 Test Flight Boosts IPO Momentum Ahead of Historic Market Debut 
X Corp Loses Legal Battle Over Australia Child Safety Fine 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
Johnson & Johnson is set to pay $230 million to settle a legal case over claims it encouraged and bolstered the opioid addiction predicament in the state of New York. Then again, it was mentioned that despite settling, the company did not acknowledge liability or any wrongdoing in what it was accused of.
What the J&J settlement means
As per BBC News, Johnson & Johnson settlement effectively prevented it from going to trial that is set to start on Tuesday, June 29. The hearing will present a number of opioid manufacturers and distributors as the defendants of the case.
The company said that its agreements with New York State are proportionate with the previous resolution to pay $5 billion to settle the opioid claims. It was added that the arrangement also requires Johnson & Johnson to discontinue the sale of painkillers across the country.
"The opioid epidemic has wreaked havoc on countless communities across New York state and the rest of the nation, leaving millions still addicted to dangerous and deadly opioids," Letitia James, the New York attorney general, said. "Johnson & Johnson helped fuel this fire, but today they're committing to leaving the opioid business - not only in New York but across the entire country."
J&J to take its problematic painkillers off the market
It was mentioned that addiction to opioids, both legal and illegal drugs, has become a serious issue, and this problem is ongoing in countries like the United States. In fact, based on the record of the Centers for Disease Control and Prevention, the country reported almost half a million deaths due to overdoses between the years 1999 and 2019.
While Johnson & Johnson is set to be removed from the trial in New York, it is still facing similar cases in other states such as California. At any rate, the deal with New York also asked the company to stop selling opioids, and it was learned that J&J already did so for some time now.
CNBC reported that Johnson & Johnson confirmed it has ended its opioid business a while ago, even before the settlement with New York. Since 2015, the company stopped marketing opioids in the U.S. and totally withdrew from the business in 2020.
